PARMA EMPAGLOW DUO Tablets 12.5/1000 mg (Empagliflozin, Metformin Hydrochloride)

Adult dose

The recommended dosage for this medication is 1 tablet once, twice a day. This should be determined considering the therapy, efficacy, and tolerability of each patient, ensuring not to exceed 25 mg of empagliflozin and 2000 mg of metformin. If using metformin alone or in combination with insulin or other medications and sufficient blood sugar control is not achieved, it is recommended to take 5 mg of empagliflozin twice a day (total daily dose of 10 mg) with the existing dose of metformin. If tolerability is excellent and additional blood sugar control is needed, empagliflozin can be increased to 25 mg (total daily dose). Patients switching to this medication from a combination of empagliflozin (total daily dose of either 10 mg or 25 mg) and metformin should use their prior doses.

This medication is used to lower blood sugar and should not be administered to patients with impaired kidney function or certain diseases. There may be a rare side effect of severe lactic acidosis, so if symptoms such as muscle pain, breathlessness, weakness, or abdominal pain occur, immediate medical attention is required. When used in conjunction with insulin or other diabetes medications, hypoglycemia may occur, so careful monitoring of blood sugar levels is necessary. Patients with reduced kidney function or conditions that can cause acute kidney injury should not take this medication or should temporarily discontinue it, and regular kidney function tests should be conducted. Urinary infections or genital infections may occur; hence, immediate treatment is required when there are signs of infection. Women who are pregnant or breastfeeding should not take this medication for safety reasons, especially breastfeeding should be discontinued. In elderly patients, there is a higher risk of fluid loss, so fluid status should be managed properly, and kidney function should be monitored frequently. Before surgery or radiographic examinations involving contrast agents, this medication should be discontinued, and it can be resumed once kidney function returns to normal after the examination. It is recommended to avoid alcohol consumption while taking this medication, and if any abnormal reactions occur, consult a doctor or pharmacist. Regular blood tests and symptom observation should be conducted to ensure the safe use of the medication.

Serious side effects

Hives, severe swelling (edema), chest tightness, difficulty breathing, cold sweat, pallor, severe allergic reactions, severe rashes with high fever, blisters, peeling skin, pain in mouth/eye mucosa, severe skin reactions, shortness of breath or difficulty breathing, asthma attacks, respiratory issues accompanied by cough and fever, yellowing of the skin or eyes (jaundice), profound lethargy, liver abnormalities (jaundice), sudden

Mild side effects

• Hypoglycemia
• urinary tract infections
• genital infections
• increased urination
• nausea
• vomiting
• diarrhea
• abdominal pain
• loss of appetite
• constipation

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. The recommended storage temperature is between 1 and 30 degrees Celsius at room temperature.

Appearance

Biconvex, oval film-coated tablet that is dark brownish-purple

Package unit

60 tablets/box [10 tablets/PTP x 6], 10 tablets/box [10 tablets/PTP x 1], 30 tablets/bottle, 60 tablets/bottle